AmpliPhi Biosciences (APHB) – Company Press Releases
-
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
-
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
-
Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs
-
Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs
-
Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress
-
Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals
-
Armata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference
-
Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs
-
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
-
Armata Pharmaceuticals Announces Participation in Upcoming Investor Conferences
-
AmpliPhi Biosciences Announces Stockholder Approval of Business Combination with C3J Therapeutics
-
AmpliPhi Biosciences Reports First Quarter 2019 Financial Results and Business Highlights
-
C3J Therapeutics Announces Issuance of U.S. Patent Covering Synthetic Bacteriophage
-
AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
-
AmpliPhi Biosciences and C3J Therapeutics Agree to Merge
-
AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development
-
Analysis: Positioning to Benefit within Artisan Partners Asset Management, Gamco Investors, Eiger BioPharmaceuticals, Waddell & Reed Financial, AmpliPhi Biosciences, and Limbach — Research Highl
-
AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights
-
Camallergy Appoints Baxter Phillips III as Chief Executive Officer
-
AmpliPhi Biosciences Announces Closing of Public Offering
-
AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering
-
AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference
-
AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018
-
AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections
-
AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections
-
AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01
-
AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program
-
AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results and Business Highlights
-
AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting
-
AmpliPhi Biosciences Announces Presentation of AB-PA01 Bacteriophage Therapy Case Study at 41st European Cystic Fibrosis Conference
-
AmpliPhi Biosciences to Present at 5th World Congress on Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance 2018
-
AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights
-
AmpliPhi Biosciences to Hold 2018 First Quarter and Business Update Conference Call on May 15
-
AmpliPhi Biosciences Will Utilize NIAID Preclinical Services to Advance Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus
-
AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Study at ISHLT Annual Meeting
-
AmpliPhi Biosciences Announces Closing of Registered Direct Offering of Common Stock
-
AmpliPhi Biosciences Announces Registered Direct Offering of Common Stock
-
AmpliPhi to Collaborate with Western Sydney Local Health District and Westmead Institute for Medical Research on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01
-
AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights
-
AmpliPhi to Collaborate with the U.S. Department of Veterans Affairs on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01
-
AmpliPhi Biosciences Announces Presentation of Preclinical Data Demonstrating that AB-PA01 Reduces Biofilm in Pseudomonas aeruginosa In Vivo Model
-
AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common Stock
-
AmpliPhi Biosciences Announces Proposed Public Offering of Common Stock
-
AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01
-
AmpliPhi Biosciences to Present at Biotech Showcase 2018
-
AmpliPhi Biosciences Provides Corporate and Strategic Update
-
AmpliPhi Biosciences to Present at LD Micro 10th Annual Main Event
-
AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights
-
AmpliPhi Biosciences to Hold 2017 Third Quarter and Business Update Conference Call on November 14
-
AmpliPhi Biosciences to Participate in the BIO-Europe 2017 Conference
Back to APHB Stock Lookup
